Corp Symetryx serves as Executive at NeuBase Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Corp Symetryx has executed 7 insider transactions totaling $772.2K, demonstrating a bearish approach to their equity position. Their most recent transaction on Sep 18, 2023 involved selling 50,000 shares valued at $59.5K.
Corp Symetryx currently holds 50,000 shares of NeuBase Therapeutics, Inc. (NBSE), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Corp Symetryx has been a net seller of NBSE stock. They have purchased $59.9K and sold $712.4K worth of shares.
Corp Symetryx's most recent insider trade was on Sep 18, 2023, when they sold 50,000 shares at $1.19 per share.
Get notified when new Form 4 filings are submitted
| $1.26 |
| Discretionary |
| Sep 14, 2023 | NBSE | $185.9K | Sale | 129,108 | $1.44 | Discretionary |
| Sep 11, 2023 | NBSE | $4.9K | Sale | 3,376 | $1.44 | Discretionary |
| Sep 8, 2023 | NBSE | $197.1K | Sale | 128,847 | $1.53 | Discretionary |
| Sep 7, 2023 | NBSE | $134.7K | Sale | 74,852 | $1.80 | Discretionary |
| Sep 1, 2023 | NBSE | $59.9K | Purchase | 61,076 | $0.98 | Discretionary |